The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?

The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? Curr Diab Rep (2017) 17: 124 https://doi.org/10.1007/s11892-017-0954-4 MACROVASCULAR COMPLICATIONS IN DIABETES (VR ARODA AND A GETANEH, SECTION EDITORS) The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? 1 1,2 Laurentiu M. Pop & Ildiko Lingvay Published online: 23 October 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Sulphonylurea Cardiovascular disease . . . Purpose of Review Sulfonylureas (SUs) are one of the most Cardiovascular safety Type 2 diabetes Healthcare cost commonly used glucose-lowering agents worldwide. While Ischemic preconditioning their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings With no dedicated cardiovascular studies Introduction to definitively answer this question, observational studies and meta-analyses abound and have reported divergent The safety profile of pharmacologic agents plays an important results, fueling the controversy. Studies that compared role in defining their risk-benefit ratio, especially when these SUs to metformin or newer agents, like GLP-1 agonists agents are used to treat chronic morbidities which require life- and SGLT2 inhibitors, suggest a difference in cardiovas- long management, like type 2 diabetes mellitus (T2DM). The cular events, yet this is likely the result of beneficial treatment armamentarium for T2DM has expanded impres- effects of the latter. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Diabetes Reports Springer Journals

The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?

Loading next page...
 
/lp/springer_journal/the-infamous-famous-sulfonylureas-and-cardiovascular-safety-much-ado-Vfq5l0CmQe
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Diabetes
ISSN
1534-4827
eISSN
1539-0829
D.O.I.
10.1007/s11892-017-0954-4
Publisher site
See Article on Publisher Site

Abstract

Curr Diab Rep (2017) 17: 124 https://doi.org/10.1007/s11892-017-0954-4 MACROVASCULAR COMPLICATIONS IN DIABETES (VR ARODA AND A GETANEH, SECTION EDITORS) The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? 1 1,2 Laurentiu M. Pop & Ildiko Lingvay Published online: 23 October 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Sulphonylurea Cardiovascular disease . . . Purpose of Review Sulfonylureas (SUs) are one of the most Cardiovascular safety Type 2 diabetes Healthcare cost commonly used glucose-lowering agents worldwide. While Ischemic preconditioning their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings With no dedicated cardiovascular studies Introduction to definitively answer this question, observational studies and meta-analyses abound and have reported divergent The safety profile of pharmacologic agents plays an important results, fueling the controversy. Studies that compared role in defining their risk-benefit ratio, especially when these SUs to metformin or newer agents, like GLP-1 agonists agents are used to treat chronic morbidities which require life- and SGLT2 inhibitors, suggest a difference in cardiovas- long management, like type 2 diabetes mellitus (T2DM). The cular events, yet this is likely the result of beneficial treatment armamentarium for T2DM has expanded impres- effects of the latter.

Journal

Current Diabetes ReportsSpringer Journals

Published: Oct 23, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off